NCT05408936

SGLT2 Inhibitors and Effects on Hematopoiesis, Inflammation and Metabolic Markers

Study of the Mechanisms Leading to Increased Hemoglobin Levels and of the Cardiorenal Response in Type 2 Diabetic Patients With Recent Initiation of SGLT2 Inhibitors.

• Status: Active Not Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 80 (actual)
• Sponsor: University of Patras · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Study of the response to SGLT2 inhibitors in type 2 diabetic patients with relevance to the erythropoesis and indexes of cardiorenal function. The study enrolls type 2 diabetic patients in whom the introduction of a SGLT2 inhibitor is deemed necessary as part of their routine treatment during their visit to our outpatient diabetes unit. A whole blood, a serum and a urine sample is obtained before and one month after the initiation of treatment with a SGLT2 inhibitor.

Conditions

• Diabetes Mellitus, Type 2

Interventions

Type	Name	Description
DRUG	SGLT2 inhibitor	Patients receive an SGLT2 inhibitor as part of theirn routine care.

Timeline

• Start date: 2022-06-03
• Primary completion: 2023-12-01
• Completion: 2024-06-01
• First posted: 2022-06-07
• Last updated: 2024-05-14

Locations

1 site across 1 country: Greece

Regulatory

• FDA-regulated drug study